Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billion

As Novo Nordisk and Eli Lilly duke it out in the weight-loss drug market with Ozempic, Wegovy and Mounjaro, drug company competitors plan to join the fray.

from Health and Science https://ift.tt/6oeIvQa
https://ift.tt/6uSHDaE
https://ift.tt/f4QTkRy